Biogen (BIIB) Tops Q1 EPS by $1.40
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
April 22, 2020 10:12 AM EDTSunTrust analyst Robyn Karnauskas reiterated a Buy rating and $360.00 price target on Biogen (NASDAQ: BIIB), telling clients to 'buy on weakness'
Karnauskas notes the company updated their Alzheimer's Disease (AD) filing timelines from early 2020 to a rolling BLA, with completion by 3Q20,... More
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... More